FINWIRES · TerminalLIVE
FINWIRES

市場動態:日本核能企業利用虛擬實境技術解決技術工人短缺問題

By

-- 根據《日經新聞》週四報道,隨著日本自2011年福島核事故以來首次考慮建造新的反應堆,日本核設備製造商正利用虛擬實境和數位工具加快員工培訓。 IHI(東京證券交易所代碼:7013)於今年1月推出了一項新的焊接培訓項目,該項目結合了課堂教學、實踐操作和透過配備攝影機的焊接面罩拍攝的影片資料。報道稱,該公司表示,該系統可以將部分技術人員的培訓時間縮短至先前的五分之一左右。 報告稱,三菱重工(東京證券交易所代碼:7011)已開發了約50門基於虛擬實境技術的課程,涵蓋核電站的設計、建造和維護;而日立公司正在將其技術專長數位化,以改善其核電業務的知識轉移。 報告指出,儘管人工智慧驅動的電力消費需求不斷增長,且政府對核電的支持力度加大,但日本核電產業仍面臨熟練勞動力短缺的問題。近期日本股市交易中,IHI股價上漲近6%,三菱重工股價下跌近2%。 (市場動態消息來自與全球市場專業人士的交流。我們認為這些資訊來自可靠管道,但可能包含傳聞和推測。準確性無法保證。)

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661